Florida-based psychedelics firm Enveric Biosciences (NASDAQ: ENVB), which is still in the pre-revenue stage, this week reported a $9.5 million net loss for 2024, down from the $17.4 million it lost in 2023 but still well in the red as it continues developing non-hallucinatory treatments for mental health disorders.
The yearly…
Please login to read all 356 words.
